Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Aga Khan University enrols first COPCOV Pakistan participant

COPCOV

As the world anxiously awaits COVID-19 vaccines, people working in healthcare settings remain at risk of infection from COVID-19. The Pakistani arm of COPCOV, the global study to test if hydroxychloroquine or chloroquine can prevent COVID-19 in healthcare workers, has begun to enrol participants at Aga Khan University, joining sites in the UK and Thailand.

Pakistan Principal Investigator Prof. M. Asim Beg and two colleagues in a hospital setting.

On 17 Nov, the Pakistan arm of COPCOV enrolled its first participant at Aga Khan University (AKU), Karachi, as COPCOV Pakistan PI Prof. M. Asim Beg looked on. Prof. Beg will be supported by AKU’s Drs Farah Qamar, Faisal Mahmood, Noshin Nasir, Momin Qazi, Sonia Qureshi and Najia Ghanchi as well as Prof. Saeed Hamid, director of AKU’s Clinical Trials Unit.

Pakistan joins Thailand and COPCOV UK sites in participating in COPCOV, the MORU-led, Oxford-supported global study to test if hydroxychloroquine or chloroquine can prevent COVID-19 in healthcare workers. AKU expects to enrol 400 participants, with new COPCOV sites in Indonesia and Kenya expected to begin enrolment in late Nov-early Dec.

Send us an enquiry if you are interested in setting up a COPCOV clinical study site in your country.

Similar stories

Rise in COPCOV numbers continues; study to end recruitment 30 Nov

A global study examining the impact of chloroquine / hydroxychloroquine in preventing COVID-19, COPCOV has recruited 3,386 participants as of 26 Oct from sites in Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Pakistan, Zambia, and closed sites in Thailand, Niger and the UK. Last week, the COPCOV team agreed with active site research teams that it will continue to recruit new participants until 30 Nov 2021, with preliminary study results expected Q1 2022.

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

The COPCOV Trial’s position statement on “A living WHO guideline on drugs to prevent COVID-19.”

Following WHO recommendations against the use of hydroxychloroquine in the prevention of COVID-19, including its use in controlled trials, we are reviewing the guideline and available evidence. We are concerned that this judgement from the authors of the guideline is scientifically unsound.

Hydroxychloroquine doses in COVID-19 prevention trials should be safe, study finds. Now let’s find out if they’re effective.

As the world waits impatiently for a COVID-19 vaccine, an exhaustive review of hydroxychloroquine and chloroquine pharmacology suggests that the doses used in COVID-19 prevention trials are safe, say University of Oxford affiliated researchers in a study published in PLoS Medicine.

Hydroxychloroquine is being discarded prematurely in COVID-19 prevention

Hydroxychloroquine could still prevent COVID-19 and save tens of thousands of lives around the world, say leading scientific researchers. While it doesn’t work in treatment of hospitalised patients, it could still prevent infections. However, fraudulent data, unjustified extrapolation and exaggerated safety concerns together with intense politicisation and negative publicity may stop COPCOV, the only large, global clinical trial testing hydroxychloroquine in COVID-19 prevention, from ever finding out.